E16. Amenorrhoea, aromatase inhibitors, tamoxifen or a combination in premenopausal women
نویسنده
چکیده
The ovary is the major site of oestrogen production in premenopausal women. Removal of the ovaries in premenopausal patients with breast cancer has long been recognised to potentially alter the course of disease. This procedure leads to a marked reduction in the circulating levels of oestrogen. It has been shown that ovariectomy given as an adjuvant treatment reduces the odds of recurrence or death by approximately 25%. Goserelin and other luteinising hormone-releasing hormone (LHRH) analogues produce reversible ovarian suppression by downregulating gonadotropin release via the LHRH receptors of the pituitary gland. Downregulated receptors lead to an inhibition of LH secretion, which causes a blockade in ovarian function. Currently, there are at least five different kinds of adjuvant treatment in premenopausal patients presenting with hormone-responsive tumours: 1. Chemotherapy 2. Tamoxifen 3. Ovarian ablation 4. LHRH analogue 5. LHRH analogue combined with tamoxifen
منابع مشابه
Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference.
Endocrine treatment for breast cancer was introduced more than a century ago. The discovery of hormone receptors has allowed targeting of endocrine treatment to patients whose primary tumours express these receptors. In the adjuvant setting, different approaches are used in premenopausal or postmenopausal women. In premenopausal patients, suppression of ovarian function and the use of tamoxifen...
متن کاملExpanding role of ovarian suppression/ablation in premenopausal ER-positive breast cancer: issues and opportunities.
Luteinizing hormone-releasing hormone analogs (LHRHa) are often used alone or in combination with tamoxifen to suppress ovarian function in premenopausal women with endocrine-responsive breast cancer. However, aromatase inhitiors (AIs) are now the preferred first-line endocrine treatment for postmenopausal women with breast cancer. Their benefits over tamoxifen in postmenopausal patients and th...
متن کاملThe Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer.
The optimal endocrine therapy for premenopausal women with early and advanced breast cancer still remains an important and controversial issue. For over 30 years, tamoxifen has been the gold standard in the adjuvant setting. New therapeutic options, such as the addition of ovarian function suppression to oral endocrine therapy (either tamoxifen or aromatase inhibitors), can improve outcomes ove...
متن کاملNew stars in the sky of treatment for early breast cancer.
Since Sir George Beatson observed in 1896 that breast tumors in premenopausal women sometimes regressed after oophorectomy, 1 numerous investigations have established that estrogen stimulates the growth of breast-cancer cells. Three newer strategies reduce the growth-stimulating signals of estrogen: interfering with the binding of estrogen to its receptor, the primary mode of action of the anti...
متن کاملOptimizing endocrine therapy in premenopausal ER-positive breast cancer patients.
In the metastatic setting, ovarian suppression in combination with tamoxifen has been shown to be more effective than either modality alone in treating hormone receptor–positive disease.[1] Small studies presented to date in abstract form also suggest that ovarian suppression in combination with aromatase inhibition is highly active in this setting.[2,3] In the treatment of premenopausal women ...
متن کامل